Apolipoprotein E genotyping in Egyptian diabetic nephropathy patients
Mohamed I Atta1, Khadiga Abo Gabal2, Khalid El-Hadidi1
1Internal Medicine Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.
Abstract:
Research for the causes of diabetic nephropathy has focused on the study of the affected familial disease clusters. The polymorphism in apolipoprotein E (ApoE) has been linked to the development of diabetic nephropathy (DN) in association with hyperlipidemia. The aim of this study was to evaluate the association of this condition with ApoE gene polymorphism connected with DN in diabetic Egyptian subjects. One hundred and thirty-five patients were enrolled in the study, they were divided into three groups: 45 diabetic patients; 45 DN patients and 45 healthy control group. Clinical examination and routine laboratory investigations with serum lipids and urinary microalbumin were done. Peripheral blood leukocytes from all were examined by the polymerase chain reaction for polymorphisms in ApoE gene. Our results revealed significant difference between Apo E genotype frequencies among all studied groups. Genotypes ε2ε3 and ε2ε4 were reported to be significantly higher in diabetes as compared to control individuals while genotype ε3ε3 was higher in control as compared to diabetes. Among the entire diabetic group ε2ε3 was highly detected in DN. Regarding allelic frequency ε2 allele was significantly detected in DN patients as compared to diabetic patients and it was the lowest in control individuals. In conclusion Apo ε2 mutations may have a role in increasing the development of DN among the Egyptian individuals. © 2015 IUBMB Life, 68(1):58-64, 2016.
More Related Videos
09:34Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
10:31Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Nephrotic Syndrome II : Assessment and Medical Management
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
